Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gimsing

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|June 3, 1998
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study groupH Brincker, J Westin, N Abildgaard, et al.
Gene|November 11, 2017
Drug response prediction in high-risk multiple myelomaA J Vangsted, S Helm-Petersen, J B Cowland, et al.
Leukemia Research|October 23, 1998
S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myelomaP de Nully Brown, P O Jensen, M Diamant, et al.
Scandinavian Journal of Haematology|October 1, 1982
Cobalamin forms in plasma and tissue during treatment of vitamin B12 deficiencyP Gimsing, E Hippe, I Helleberg-Rasmussen, et al.
Scandinavian Journal of Immunology|November 4, 2010
Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myelomaM K Brimnes, A J Vangsted, L M Knudsen, et al.
International Journal of Laboratory Hematology|March 31, 2016
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translationN E U Hermansen, R Borup, M K Andersen, et al.
European Journal of Haematology|August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology|January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)P Gimsing, O W Bjerrum, E Brandt, et al.
Bone Marrow Transplantation|November 11, 2008
The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTA J Vangsted, T W Klausen, W Ruminski, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|June 3, 1998
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study groupH Brincker, J Westin, N Abildgaard, et al.
Gene|November 11, 2017
Drug response prediction in high-risk multiple myelomaA J Vangsted, S Helm-Petersen, J B Cowland, et al.
Leukemia Research|October 23, 1998
S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myelomaP de Nully Brown, P O Jensen, M Diamant, et al.
Scandinavian Journal of Haematology|October 1, 1982
Cobalamin forms in plasma and tissue during treatment of vitamin B12 deficiencyP Gimsing, E Hippe, I Helleberg-Rasmussen, et al.
Scandinavian Journal of Immunology|November 4, 2010
Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myelomaM K Brimnes, A J Vangsted, L M Knudsen, et al.
International Journal of Laboratory Hematology|March 31, 2016
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translationN E U Hermansen, R Borup, M K Andersen, et al.
European Journal of Haematology|August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology|January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)P Gimsing, O W Bjerrum, E Brandt, et al.
Bone Marrow Transplantation|November 11, 2008
The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTA J Vangsted, T W Klausen, W Ruminski, et al.
Bone Marrow Transplantation|June 30, 2015
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialP Gimsing, Ø Hjertner, N Abildgaard, et al.
Pageof 5